Show simple item record

dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorKavak, Engin Eren
dc.contributor.authorTopçu, Atakan
dc.contributor.authorBayramgil, Ayberk
dc.contributor.authorAkgül, Fahri
dc.contributor.authorKahraman, Seda
dc.contributor.authorAykan, Musa Barış
dc.contributor.authorAltıntaş, Yunus Emre
dc.contributor.authorHelvacı, Kaan
dc.contributor.authorÜrün, Yüksel
dc.contributor.authorBilici, Ahmet
dc.contributor.authorŞeker, Mesut
dc.identifier.citationGöktaş Aydın, S., Kavak, E. E., Topçu, A., Bayramgil, A., Akgül, F., Kahraman, S. ... Şeker, M. (2023). Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study. Biomolecules and Biomedicine, 23(6), 1089-1095.
dc.description.abstractRegorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing regorafenib treatment and assess the optimal dosing regimen in a real-life setting. We retrospectively analyzed 263 patients with mCRC from multiple medical oncology clinics in Turkey. Treatment responses and prognostic factors for survival were evaluated using univariate and multivariate analysis. Of the patients, 120 were male and 143 were female; 28.9% of tumors were located in the rectum. RAS mutations were present in 3.0% of tumors, while BRAF, K-RAS, and N-RAS mutations were found in 3.0%, 29.7%, and 25.9% of tumor tissues, respectively. Dose escalation was preferred in 105 (39.9%) patients. The median treatment duration was 3.0 months, with an objective response rate (ORR) of 4.9%. Grade ≥ 3 treatment-related toxicity occurred in 133 patients, leading to discontinuation, interruption, and modification rates of 50.6%, 43.7%, and 79.0%, respectively. Median progression-free survival (PFS) and overall survival (OS) were 3.0 and 8.1 months, respectively. RAS/RAF mutation (hazard ratio [HR] 1.5, 95% confidence interval [CI] 1.1–2.3; P = 0.01), pre-treatment carcinoembryonic antigen (CEA) levels (HR 1.6, 95% CI 1.1–2.3; P = 0.008), and toxicity-related treatment interruption or dose adjustment (HR 1.6, 95% CI 1.1–2.4; P = 0.01) were identified as independent prognostic factors for PFS. Dose escalation had no significant effect on PFS but was associated with improved OS (P < 0.001). Independent prognostic factors for OS were the initial TNM stage (HR 1.3, 95% CI 1.0–1.9; P = 0.04) and dose interruption/adjustment (HR 0.4, 95% CI 0.2–0.9; P = 0.03). Our findings demonstrate the efficacy and safety of regorafenib. Treatment line influences the response, with dose escalation being more favorable than adjustment or interruption, thus impacting survival.en_US
dc.publisherAssociation of Basic Medical Sciences of FBIHen_US
dc.rightsAttribution-NonCommercial 4.0 International*
dc.subjectDose Escalationen_US
dc.subjectDose Interruptionen_US
dc.subjectMetastatic Colorectal Cancer (mCRC)en_US
dc.subjectOverall Survival (OS)en_US
dc.subjectProgression-Free Survival (PFS)en_US
dc.titlePrognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center studyen_US
dc.relation.ispartofBiomolecules and Biomedicineen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.institutionauthorGöktaş Aydın, Sabin
dc.institutionauthorBilici, Ahmet

Files in this item


This item appears in the following Collection(s)

Show simple item record

Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess